CLAIM CARD
The evidence base for aspirin in various clinical contexts draws heavily from meta-analyses of dual antiplatelet therapy (DAPT) regimens following percutaneous coronary intervention (PCI). Complementing this, a separate meta-analysis of randomized trials evaluating early aspirin withdrawal in high-risk post-PCI patients found that aspirin cessation was associated with a significant reduction in major bleeding (P < 0.001) without a concomitant increase in ischemic events (Navarese 2026). These findings collectively suggest that within the specific context of post-PCI management, aspirin's role may be modifiable without catastrophic ischemic consequence, a nuance critical for assessing its broader geroprotective utility.
Evidence grade: exploratory
Contradiction status: none
Publication: 4ff5f065-8b09-4580-9cbc-da14dbcaa1fa
Provenance: Derivation Web chain
Citation Support
source_1Flensted-Jensen 2025source_2Saeed 2026source_3Zhu 2026source_4Navarese 2026source_5Yan 2024